Report
GW Pharmaceuticals Re Sativex




RNS Number:8627J
GW Pharmaceuticals PLC
13 December 2007



GW Welcomes Move by UK Regulator to Provide More Information for Sativex(R)
Prescribers


Porton Down, UK; 13 December 2007: GW Pharmaceuticals plc (AIM: GWP) welcomes
the publication today by the UK regulator, the Medicines & Healthcare products
Regulatory Agency (MHRA) of a Public Information Report on Sativex(R), GW\'s
cannabinoid spray medicine.


The MHRA has taken this unprecedented step due to its view of the \"huge public
interest\" in Sativex and the fact that approximately 1400 patients in the UK
have so far received the medicine on prescription on a named patient basis. New
patients continue to be prescribed Sativex every day. Hence, the MHRA considers
that it is in the public interest for potential prescribers to have further
information on the medicine.


Dr Geoffrey Guy, Chairman, said, \"We welcome the MHRA\'s appreciation of the
public interest in Sativex and recognition of the extent of prescription use of
Sativex in the UK. We continue to receive enquiries from UK physicians and
patients on a daily basis and this report will serve to provide them with more
information about the medicine and its use.\"


Dr Guy added, \"As we have previously announced, there is an outstanding efficacy
issue to be resolved prior to full regulatory approval for Sativex in the relief
of Multiple Sclerosis spasticity. This issue, detailed in the report, is being
addressed through an additional Phase III clinical trial, which commenced
recently.\"



Enquiries:

GW Pharmaceuticals plc Today: +44 20 7831 3113

Dr Geoffrey Guy, Chairman Thereafter: + 44 1980 557000
Justin Gover, Managing Director
Mark Rogerson, Press and PR Tel: + 44 7885 638810

Financial Dynamics Tel: +44 20 7831 3113

David Yates

Its been a long wait, but looking very positive now.

been holding these for 3 years and were as interesting as watching paint dry....in the money at last now